WINTON GROUP Ltd Acquires New Shares in Boston Scientific Corporation $BSX

WINTON GROUP Ltd acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 147,742 shares of the medical equipment provider’s stock, valued at approximately $14,424,000. Boston Scientific makes up approximately 0.5% of WINTON GROUP Ltd’s investment portfolio, making the stock its 29th largest position.

Several other large investors also recently made changes to their positions in the stock. Gerber Kawasaki Wealth & Investment Management raised its stake in shares of Boston Scientific by 3.8% in the 2nd quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 99 shares in the last quarter. Crown Wealth Group LLC boosted its position in Boston Scientific by 4.7% during the third quarter. Crown Wealth Group LLC now owns 2,238 shares of the medical equipment provider’s stock worth $218,000 after purchasing an additional 100 shares during the period. Sound View Wealth Advisors Group LLC grew its holdings in Boston Scientific by 3.9% during the second quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 103 shares during the last quarter. Cary Street Partners Investment Advisory LLC raised its position in shares of Boston Scientific by 5.1% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after purchasing an additional 103 shares during the period. Finally, Scotia Capital Inc. raised its position in shares of Boston Scientific by 0.7% in the second quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider’s stock valued at $1,621,000 after purchasing an additional 104 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $71.24 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market cap of $105.71 billion, a PE ratio of 36.72, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. The firm has a fifty day moving average price of $85.03 and a two-hundred day moving average price of $94.47. Boston Scientific Corporation has a fifty-two week low of $70.75 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the prior year, the business earned $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the subject of several recent analyst reports. BTIG Research reaffirmed a “buy” rating on shares of Boston Scientific in a report on Wednesday, February 4th. Royal Bank Of Canada cut their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Needham & Company LLC lowered their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. JPMorgan Chase & Co. dropped their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Finally, UBS Group cut their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $108.36.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.